News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article first appeared on GuruFocus. Revenue: $5 billion, up 4.4% on an FX-neutral basis. Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year. Adjusted Gross Margin: 54.3%, down 100 basis points versus the prior year. Adjusted EPS: $3.23, up 4.9%. …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Becton Dickinson (BDX) stock saw a minimal slip of 0.1% despite strong adjusted earnings per share of US$3.23 and a solid operating margin of 24.9% in its Q3 2026 earnings report. While the company's "New BD" strategy is showing positive signs like FX-neutral revenue …
RBC Capital Markets highlighted Becton, Dickinson and Company's fiscal third-quarter results as indicative of progress despite significant economic challenges. The firm acknowledged the company's efforts in managing headwinds like foreign exchange and inflation, which were largely offset by strong operational performance and effective cost …
Becton, Dickinson and Company's (BDX) average 12-month price target has been increased to $187.18 by 11 analysts, up from $178.2, implying a 10% potential upside from its Aug. 5 closing price. The consensus rating for the stock remains a "Buy" among 16 analysts, with …
Becton Dickinson raised the lower end of its annual adjusted profit forecast for 2026 after exceeding Wall Street estimates for its third-quarter profit and revenue. The company attributed this performance to strong demand for its drug-delivery devices and surgical equipment. Despite potential cost increases …
Becton Dickinson director Carrie L. Byington was granted 94 rights to Common Stock under the BD Deferred Compensation Plan, with each right valued at $165.62. This transaction increases her total plan rights to 3,810, including those acquired through dividend reinvestment. These rights convert one-for-one …
Becton, Dickinson and Company (BDX) has filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. Key highlights include the completion of the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation, generating a …
Polen, representing BD (Becton, Dickinson and Company), is highlighting a "New BD" focus and significant product innovation. This strategic shift and new developments have led the company to raise its earnings outlook for 2026. The article indicates a positive financial forecast driven by these …
Becton, Dickinson and Company (BDX) reported strong Q3 fiscal 2026 results, surpassing analyst expectations with an EPS of $3.23 and revenue of $4.98 billion. The company showed robust financial health, including a 44.6% increase in year-to-date free cash flow, and updated its full-year guidance, …
Becton Dickinson (BDX) has raised its full-year earnings guidance following strong third-quarter results that surpassed Wall Street expectations. The medical device maker reported revenue gains across all its divisions, leading to an updated adjusted per-share earnings forecast of $12.62 to $12.72 for the year. …
The medical-technology stock has regained ground across weekly windows, but confirmation remains uneven before the Aug. 6 report.
For the quarter ended June 2026, Becton Dickinson (BDX) reported revenue of $4.98 billion, down 9.6% over the same period last year. EPS came in at $3.23, compared to $3.68 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%This article announces the publication of Becton, Dickinson and Company's (BDX) Q3 2026 earnings call presentation. The slide deck was released in conjunction with their earnings call, providing details on their financial results for the quarter. The publication is handled by Seeking Alpha's transcripts …
Becton Dickinson (BDX) reported Q3 earnings of $3.23 per share and revenues of $4.98 billion, both exceeding Zacks Consensus Estimates. Despite outperforming expectations for the past four quarters, the stock has underperformed the S&P 500 this year, leading to a Zacks Rank #4 (Sell) …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Becton, Dickinson and Company reported stronger-than-expected Q3 2026 financial results, with adjusted earnings per share of $3.23 exceeding estimates and revenue reaching $4.98 billion. The company saw robust growth in its Interventional segment, and management provided optimistic guidance for the full fiscal year 2026. …
Becton Dickinson (BDX) stock rose 1.8% in pre-open trading after the medical technology company reported fiscal Q3 2026 earnings that surpassed Wall Street expectations for both revenue and EPS. The company also raised its full-year fiscal 2026 adjusted diluted EPS guidance, signaling increased confidence …
Becton Dickinson and Company (NYSE:BDX) reported third-quarter results that surpassed analyst expectations for both earnings per share and revenue. The company posted adjusted EPS of $3.23 on revenue of $5.0 billion, exceeding estimates of $3.13 and $4.89 billion, respectively. Following these strong results, Becton …
Becton, Dickinson and Company (BDX) reported its Q3 revenue at $4.98 billion. The company also expects its fiscal 2026 adjusted EPS to range from $12.62 to $12.72, aligning with FactSet estimates. Recent analyst activities include price target adjustments and new coverage with a "Buy" …
Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectively Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion Company updates …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Bilal Muhsin, Executive Vice President and President of the Connected Care Segment at Becton Dickinson (BD), discusses the evolution of connected care in hospitals, moving from episodic data to real-time, predictive insights. He highlights how BD's integrated platforms, like BD Incada, enable smarter alert …
Becton Dickinson (BD) is set to report its fiscal fourth-quarter earnings, with investors focused on the company's transformation into a pure-play medtech business. Analysts are looking for signs of sustainable mid-single-digit growth and improved operating leverage following the spin-off of its Biosciences and Diagnostic …
Becton Dickinson (BDX) is gaining attention due to its recent partnership with EMS to launch a semaglutide therapy in Brazil using its Vystra injection pen. Despite a 10.92% share price return over 90 days, the stock is down 15.04% year-to-date and trades below analyst …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Wall Street analysts forecast that Becton Dickinson (BDX) will report quarterly earnings of $3.14 per share in its upcoming release, pointing to a year-over-year decline of 14.7%. It is anticipated that revenues will amount to $4.89 billion, exhibiting a decrease of 11.2% compared to …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Becton Dickinson & Co. (BDX) stock rose 2.77% to $170.21 on Monday, outperforming the broader market which also saw significant gains. This marks the second consecutive day of gains for the stock. The S&P 500 and Dow Jones Industrial Average also experienced strong trading …
BD (Becton, Dickinson and Company) has partnered with EMS to launch a semaglutide therapy in Brazil using BD's Vystra Injection Pen, aiming to address the rising demand for GLP-1 therapies in chronic conditions like obesity and type 2 diabetes. This collaboration is seen as …
Becton Dickinson & Co. (BDX) stock fell 1.75% on Thursday, closing at $165.45, despite an overall positive trading session for the broader market. This drop snapped a four-day winning streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average both …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Becton Dickinson stock has delivered a 20.9% one year return, yet the valuation checks send a mixed message, with the Discounted Cash Flow (DCF) …
Sharemaestro market context Price below Trend Line 52 weeks -20.7% · Next-week setup negative 16.7%Search by ticker symbol or company name and select a result to open its chart.